Biosynex Subsidiary Chembio Secures $5.7 Million for Biothreat Test Development

• Chembio Diagnostic Systems, a wholly owned Biosynex subsidiary, secured $5.7 million to develop its DPP Biothreat Panel.
• The 20-month program is supported by the Biomedical Advanced Research and Development Authority and aims to secure FDA clearance.
• The rapid point-of-care test targets pathogens responsible for plague, tularemia and melioidosis.
• The system remains under development, has not received FDA authorization or approval, and is not commercially available.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biosynex SA published the original content used to generate this news brief via EQS News (Ref. ID: fr_reg_2421488_fr) on October 23, 2026, and is solely responsible for the information contained therein.